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ABSTRACT ThecatalyticsiteoftheHIVintegraseiscontainedwithinanRNaseH-likefold,andnumerousdrugshavebeendevel-
opedthatbindtothissiteandinhibititsactivity.Herpessimplexvirus(HSV)encodestwoproteinswithpotentialRNaseH-like
folds,theinfectedcellprotein8(ICP8)DNA-bindingprotein,whichisnecessaryforviralDNAreplicationandexhibitsrecom-
binase activity in vitro, and the viral terminase, which is essential for viral DNA cleavage and packaging. Therefore, we hypothe-
sizedthatHIVintegraseinhibitorsmightalsoinhibitHSVreplicationbytargetingICP8and/ortheterminase.Totestthis,we
evaluatedtheeffectof118-D-24,apotentHIVintegraseinhibitor,onHSVreplication.Wefoundthat118-D-24inhibitedHSV-1
replicationincellcultureatsubmillimolarconcentrations.ToidentifymorepotentinhibitorsofHSVreplication,wescreeneda
panelofintegraseinhibitors,andonecompoundwithgreateranti-HSV-1activity,XZ45,waschosenforfurtheranalysis.XZ45
signiﬁcantlyinhibitedHSV-1andHSV-2replicationindifferentcelltypes,with50%inhibitoryconcentrationsthatwereap-
proximately1M,butexhibitedlowcytotoxicity,witha50%cytotoxicconcentrationgreaterthan500 M.XZ45blockedHSV
viralDNAreplicationandlategeneexpression.XZ45alsoinhibitedviralrecombinationininfectedcellsandICP8recombinase
activity in vitro. Furthermore, XZ45 inhibited human cytomegalovirus replication and induction of Kaposi’s sarcoma herpesvi-
rusfromlatentinfection.OurresultsarguethatinhibitorsofenzymeswithRNaseH-likefoldsmayrepresentageneralantiviral
strategy,whichisusefulnotonlyagainstHIVbutalsoagainstherpesviruses.
IMPORTANCE Theherpesvirusescauseconsiderablemorbidityandmortality.Nucleosideanalogshaveservedaseffectiveantivi-
ralagentsagainsttheherpesviruses,butresistancecanarisethroughviralmutation.Second-lineanti-herpesdrugshavelimita-
tionsintermsofpharmacokineticpropertiesand/ortoxicity,sothereisagreatneedforadditionaldrugsfortreatmentofher-
pesviralinfections.ThisstudyshowedthattheHIVintegraseinhibitorsalsoblockherpesviralinfection,raisingtheimportant
potentialofanewclassofanti-herpesdrugsandtheprospectofdrugsthatcombatbothHIVandtheherpesviruses.
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H
erpes simplex virus 1 (HSV-1) and HSV-2 cause considerable
morbidityandmortality,andHSV-2infectionincreasestherisk
of transmission and acquisition of HIV-1 (1). Nucleoside analogs
have been very effective as antiviral drugs to counter the herpesvi-
ruses,butHSV-1andHSV-2canevolvetoacquireresistancetothese
drugs by mutations in their thymidine kinase or DNA polymerase
genes (2). Although development of resistance was thought to occur
largely in immunocompromised or immunodeﬁcient individuals,
the frequency of resistance following treatment and prophylaxis of
eye infections has recently been recognized to be much higher than
previously thought (3, 4). Approved alternative drugs that could be
used should resistance to nucleoside analog drugs develop have lim-
itationsintermsofpharmacokineticpropertiesandtoxicities.Anew
helicase-primaseinhibitorisbeingtested(5),butadditionaldrugsare
needed to target HSV and the herpesviruses in general.
The human immunodeﬁciency virus 1 (HIV-1) integrase (IN)
enzymecatalyzestheintegrationoftheHIVDNAgenomeintothe
hostchromosome,whichisanessentialstepinHIVreplication(6,7).
ThecatalyticcoredomainoftheINenzymehasanRNaseH-likefold
that harbors the D,DX35E catalytic triad, which coordinates metal
ions(8).Inhibitorycompoundsthatbindtothemetalion,DNA,and
amino acid residues of the enzyme and block the strand transfer ac-
tivity of IN have been approved as anti-retroviral drugs (7).
The herpesviruses encode at least two protein products that
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the large subunit of the viral terminase, which in HSV is named
the pUL15 protein and in human cytomegalovirus (HCMV) the
pUL89 protein (9, 10), and the single-stranded DNA (ssDNA)-
binding protein, which in HSV is named infected cell protein 8
(ICP8) or the UL29 gene product (11). In the viral terminase sub-
unit, the carboxy-terminal domain of the HCMV pUL89 protein
showsanRNaseH-likefoldinitscrystalstructure,theproteinhas
a nuclease activity that is dependent on Mn2 ions, and the enzy-
matic activity is inhibited by raltegravir (10). Similarly, the
C-terminaldomainoftheHSV-1terminaselargesubunit,pUL15,
shows an RNase H-like fold in its crystal structure and shows
metalion-catalyzedcleavageofDNA(9).ICP8ispredictedtohave
an RNase H-like fold containing DDE residues characteristic of a
metal-binding site (11, 12). ICP8 promotes strand invasion in an
in vitro assay to form a displacement loop, or D loop (13), and
cooperates with the HSV-1 UL12 nuclease to mediate strand ex-
change between a long double-stranded linear molecule and a
circularssDNAmolecule(14).BecauseICP8(15)andpUL15(16)
areessentialforHSVreplication,wetestedwhetherHIVintegrase
inhibitors would inhibit HSV replication. We found that IN in-
hibitor compounds reduce HSV-1, HSV-2, and HCMV replica-
tion, as well as reactivation of KSHV from latent infection in cell
culture.
RESULTS
WetestedwhetherINinhibitorscouldinhibitHSVreplicationby
incubating HSV-1-infected cells in the presence of the IN inhibi-
torsraltegravir(17)and118-D-24(18)andmeasuringtheyieldof
progeny virus by plaque assay on new cells. We observed that
raltegravir (results not shown) and 118-D-24 (see Fig. S1 in the
supplemental material) inhibited HSV-1 strain KOS replication
with a submillimolar 50% effective concentration (EC50) (Fig. 1).
We further screened a series of related integrase inhibitor com-
pounds (see Table S1 in the supplemental material), and these
compounds showed various levels of inhibition of HSV replica-
tion (see Fig. S1). Several hydrazide compounds, XZ45, XZ15,
XZ49, and XZ48, showed strong inhibition of HSV replication,
reducing viral yields by ﬁve to seven orders of magnitude. In ad-
dition,twooftheoxoisoindoles,XZ100andXZ99,inhibitedHSV
replication by at least seven orders of magnitude (see Fig. S1).
More complete dose-response curves using the six most effec-
tive compounds and, as a control, the less efﬁcacious compound
XZ50 showed that XZ45 was the most potent (Fig. 2), so it was
chosen for further study of its effects on HSV replication and
cytotoxicity. XZ45 inhibited HSV-1 KOS replication in HEp-2
cells with an EC50 of 1.1 M (Fig. 3A) and in human foreskin
ﬁbroblasts (HFFs) with an EC50 of 350 nM (Fig. 3B). In contrast,
the compound showed a 50% cytotoxic concentration (CC50)o f
570MinHEp-2cellsusingtheCellTiter-Gloassay(Fig.3C).To
determine the breadth of the effects of XZ45 against HSV, we
testeditseffectonotherHSV-1andHSV-2strains.XZ45wasalso
potent and efﬁcacious for inhibition of replication of the limited-
passage HSV-1 F and HSV-2 G strains (Fig. 3D).
Todeterminethestage(s)atwhichXZ45inhibitedHSV-1rep-
lication, we examined viral protein synthesis in HEp-2 cells in-
fectedwithHSV-1KOSvirusinthepresenceorabsenceof10M
XZ45. Expression and accumulation of the immediate-early
ICP27 protein and the early ICP8 protein were not affected
through 12 hpi (Fig. 4A). However, expression of the late glyco-
proteinC(gC)wasinhibited(Fig.4A).Therefore,viralreplication
was inhibited after E gene expression and at or before L gene
expression. We therefore hypothesized that XZ45 inhibited viral
DNAreplication.InHEp-2cellsinfectedwithHSV-1KOS,10M
XZ45 inhibited viral DNA synthesis by 50-fold (Fig. 4B). The re-
ductioninviralDNAsynthesisappearedtobelessthanthe1,000-
fold reduction in viral yields observed under these conditions.
Therefore, we concluded that XZ45 inhibits HSV replication, at
least in part, at the stages of viral DNA synthesis and late gene
expression.
XZ45 inhibits HSV recombination in infected cells and in
vitro.Becausethesecompoundswereoriginallydesignedasinhib-
itorsoftheHIVIN,aDDErecombinase(19),andbecausethereis
evidence that ICP8 is involved in recombination (13, 14), we hy-
pothesized that the compounds might inhibit homologous re-
combination in HSV-infected cells. To test the effect of XZ45 on
HSVrecombinationduringviralreplication,wecoinfectedHEp-2
FIG 1 Inhibition of HSV-1 replication by 118-D-24. The effect of 118-D-24
onHSV-1replicationwastestedbyayieldreductionassayinHEp-2cells.Cells
were inoculated with HSV-1 WT KOS strain at a multiplicity of infection
(MOI)of 0.01PFU/cellfor1htoallowviralentry.Theinfectedcellswerethen
incubated in medium containing increasing concentrations of 118-D-24 or
DMSO(nodrug,vehicleonly).At48hpostinfection,sampleswereharvested,
and viral yield was determined by plaque assay on Vero cells. The reported
values are percent yield relative to cells incubated in medium containing
DMSO vehicle. Similar results were obtained in four additional independent
experiments.
FIG 2 Effects of integrase inhibitor compounds on HSV-1 replication. Var-
ious concentrations of 7 compounds were tested in a yield reduction assay in
HEp-2 cells as described for Fig. 1.
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fusion)andHSV-1hr99(UL5genelacZinsertion)mutantviruses
in the presence of increasing concentrations of either XZ45 or the
viralDNApolymeraseinhibitorphosphonoaceticacid(PAA),the
latter as a control for inhibition of viral DNA replication, to in-
hibitviralreplicationtovariousextents.At20hafterinfection,the
infected cultures were harvested, and progeny viruses were
titrated on Vero cells (which exhibit plaques only with the wild-
type [WT] recombinants) and V529 cells (which exhibit plaques
onlywiththemutantvirusesandtherecombinants)todetermine
the viral titers of recombinant WT virus and total virus, respec-
tively. When the recombination frequency was plotted relative to
levelsofviralreplication,weobservedthatasXZ45inhibitedviral
replication, the recombination frequency decreased signiﬁcantly
(P0.0117;Spearman’srankcorrelationanalysis,two-wayanal-
ysis) (Fig. 5A). In contrast, inhibition of viral DNA replication
withPAAdidnotsigniﬁcantlyalterthefrequencyofrecombinant
viruses (P  0.7966) (Fig. 5A). Therefore, XZ45 inhibits homolo-
gous recombination between viral genomes as well as inhibiting
viral DNA synthesis.
The HSV ICP8 DNA-binding protein shows in vitro strand
transfer activity, either alone (13) or in combination with a nu-
clease (14), and shows some properties of a DDE recombinase
(11). We therefore tested if XZ45 could inhibit ICP8s in vitro
recombinase activity in a strand invasion assay (13). In this assay
weincubatedICP8withanunlabeleddouble-strandedDNAmol-
ecule and a labeled single-stranded oligonucleotide, conditions
under which ICP8 has been shown to promote formation of a D
loop (13). We observed that XZ45 reduced the amount of the D
loop formed (Fig. 5B). Therefore, XZ45 seemed to inhibit in vitro
strand exchange by ICP8.
To test the hypothesis that XZ45 affects ICP8 function by in-
hibiting its binding to ssDNA, we ﬁrst performed an electropho-
reticmobilityshiftassay(EMSA)withpuriﬁedICP8proteinanda
32P-labeled ssDNA probe. XZ45 did not inhibit the ssDNA probe
bindingtoICP8,andtheremayhavebeenaslightincreaseinDNA
binding in the presence of XZ45 (Fig. 5C). Second, in an ssDNA-
coated-bead pulldown assay, we observed that XZ45 did not in-
hibit ICP8 binding to the beads when it was added either during
both infection and pulldown or during the pulldown assay only
(Fig. 5D, top). Consistent with this, XZ45 did not inhibit ICP8
binding to ssDNA-cellulose in a similar assay using HSV-1-
infected cell lysates (Fig. 5D, bottom). In total, our results argue
FIG 3 Inhibition of HSV-1, HSV-2, and HCMV replication by XZ45. (A) HSV yield reduction assay with XZ45. HEp-2 cells were infected with HSV-1 strain
KOS, and yield reduction assays were performed as described for Fig. 1. EC50 and EC90 values were calculated using nonlinear regression curve ﬁtting with a
variable slope (GraphPad Prism 5 software). (B) Effect of XZ45 on HSV-1 KOS replication in HFF cells. (C) Cytotoxicity of XZ45 on HEp-2 cells during a 48-h
incubation period was evaluated using the Promega Cell Titer-Glo assay, following the manufacturer’s instructions. The values shown are the percent ﬂuores-
cence intensity remaining relative to the ﬂuorescence intensity from cells grown in medium containing DMSO alone. The CC50 was determined as described
above. (D) Effect of XZ45 on HSV-1 or HSV-2 replication in HEp-2 cells. The methods were the same as for panel A.
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affecting its ssDNA binding.
XZ45 inhibits HCMV replication. The other human herpes-
viruses also encode homologs of the ICP8 DNA-binding protein
andthepUL15terminaselargesubunit(20);therefore,theymight
also be sensitive to these compounds. The HCMV terminase en-
zyme is sensitive to raltegravir in vitro (10), but viral replication
had not been tested. Therefore, we determined the effect of XZ45
on HCMV replication in human foreskin ﬁbroblasts (HFFs). We
incubatedHFFcellswithvariousconcentrationsofXZ45fromthe
timeofinfectionwithHCMV,harvestedtheculturesat5dpi,and
titrated the viral yields. We observed that XZ45 inhibited HCMV
replication very potently, with an EC50 of less than 50 nM and an
efﬁcacy of 104-fold reduction at 0.5 M (Fig. 6).
XZ45 inhibits KSHV reactivation from latent infection.
KSHV, a gammaherpesvirus, encodes a DNA-binding protein,
ORF6, which shares sequence homology with the ICP8 protein
(21), and a homolog of the UL15 terminase protein (22), suggest-
ing that this virus might also be sensitive to XZ45. Because KSHV
establisheslatencyuponprimaryinfection,weexaminedtheeffect
of XZ45 on KSHV reactivation. Treatment of latently infected
cells with the phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (TPA/PMA) and the histone deacetylase (HDAC) inhibi-
tor valproic acid (VA) induce reactivation of the virus (23). We
reactivated 293 cells latently infected with a recombinant KSHV
(rKSHV.219)withPMA/VAandculturedtheminthepresenceof
10 M XZ45 or dimethyl sulfoxide (DMSO) for 48 h. Treatment
with the inhibitor did not cause major cytotoxicity, as more than
90% of the cells remained viable after treatment (results not
shown). We observed a signiﬁcant increase in KSHV early ORF57
and late ORF64 transcripts upon treatment with PMA and VA
(Fig. 7). Treatment with 10 M XZ45 signiﬁcantly reduced these
viral RNAs to levels near the uninduced levels (Fig. 7A and B).
These results indicated that XZ45 inhibits KSHV reactivation
from latency.
DISCUSSION
The most successful antivirals targeting the herpesviruses have
been the nucleoside analogs (2). Under certain conditions, resis-
tancetothenucleosideanalogscanariseinHSVthroughaccumu-
lation of mutations in the viral thymidine kinase and/or DNA
polymerase genes (2, 20). There have been limited second-line
antivirals available for treatment of herpesvirus infections, but
these have limitations, and although some new antiherpesviral
drugs are in various stages of development, there remains a need
for new modalities, particularly for treatment of resistant infec-
tions(24).Theherpesvirusesencodetwoproteinsthatareknown
or predicted to contain an RNase H-like fold, which could be
targeted by drugs and compounds similar to the drugs that target
the HIV IN enzyme. A previous study had shown that raltegravir
could inhibit the nuclease activity of the HCMV pUL89 protein
(10), and we had shown that HSV-1 ICP8 had some molecular
properties of a DDE recombinase (11). We therefore tested
whether integrase inhibitors could inhibit replication of HSV and
other herpesviruses and found that certain of these compounds
were potent for inhibition of herpesviral replication. Thus, this
class of enzymatic inhibitor has potential for antiviral therapy of
herpesvirusinfectionsaswellasHIVinfections.Ourresultscould
provide a scientiﬁc basis for the effect of raltegravir against recur-
rent HSV infection in a patient with NK cell deﬁciency (25).
Mechanisms of inhibition of HSV replication. The XZ45
compoundreducesHSV-1DNAreplication,homologousrecom-
bination, and late gene expression. Thus, the earliest detectable
effect of the compound is at the stage of viral DNA replication.
Seven viral proteins are required for HSV DNA replication (26),
including the ICP8 DNA-binding protein. We observed no effect
of XZ45 on ICP8 DNA binding, but XZ45 did inhibit the strand
transfer activity of ICP8. How the strand transfer activity of ICP8
might relate to DNA synthesis is unclear. HSV DNA synthesis has
beenproposedtooccurthroughatwo-stagemechanisminwhich
the initial rounds of viral DNA synthesis are on a theta interme-
diate while later DNA synthesis occurs by a rolling circle mecha-
nism (1). Some proposed mechanisms of HSV DNA replication
involve strand transfer or recombinational mechanisms. For ex-
ample, Roizman et al. (27) proposed that strand invasion mecha-
nisms could be involved in the inversion of the L and S compo-
nents of the genome, the regeneration of terminal sequences, and
maintenance of the repeated sequences during viral DNA replica-
FIG 4 Effect of XZ45 on viral gene expression and DNA synthesis. (A) Viral gene expression. HEp-2 cells were infected with HSV-1 WT KOS at an MOI of 10
in the presence of DMSO or 10 M XZ45. Cell lysates were prepared for immunoblots at the indicated times. Polypeptides were resolved by SDS-PAGE,
transferredtoapolyvinylidenemembrane,andprobedforrepresentativeimmediate-early(ICP27),early(ICP8),andlate(gC)proteins.(B)ViralDNAsynthesis.
HEp-2cellswereinfectedwithHSV-1(KOSstrain)atanMOIof10inthepresenceofDMSOorXZ45(10M).TotalDNAwasharvestedatthetimesindicated,
and viral DNA levels in the samples were determined by real-time PCR and normalized to the levels of cellular DNA.
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the second stage of HSV DNA synthesis (28, 29). Therefore, the
recombinase activity of ICP8 could be essential for viral DNA
synthesis. Because XZ45 only partially inhibits viral DNA replica-
tion,itisinterestingtospeculatethattheenzymaticactivitythatis
inhibited involves the transition from theta form replication to
rolling circle or the second stage of viral DNA synthesis.
However,thereductioninviralDNAsynthesisat10MXZ45
is less than the reduction in viral yield, and XZ45 seems to be
inhibiting late gene expression. ICP8 is known to promote late
gene expression (30), and its recombinase activity may in some
way exert a cis-acting effect on progeny viral DNA molecules that
stimulates late gene transcription (31). XZ45 could inhibit this or
other mechanisms stimulating late gene expression. Finally, an
important part of the effect of XZ45 is likely to be exerted on the
terminase nuclease activity (9, 10) and to inhibit cleavage and
encapsidation of progeny viral DNA.
Inhibitionofotherherpesviruses.XZ45alsopotentlyinhibits
HCMV replication in human ﬁbroblasts. Raltegravir had been
shown to inhibit the HCMV terminase nuclease activity (10), and
thismaybeatleastapartofthetargetforXZ45inHCMV-infected
cells. The HCMV UL57 DNA-binding protein is highly homolo-
gous to the HSV-1 ICP8 DNA-binding protein, so this could also
be a target for XZ45 in HCMV-infected cells.
XZ45inhibitedinductionoftheKSHVearlyORF57RNAdur-
ing reactivation, so the target in KSHV-infected cells seems to be
earlier than viral DNA synthesis, or the order of gene expression
may differ from that in lytic infection. Alternatively, the target
FIG5 Effect of XZ45 on recombination and ICP8 DNA-binding. (A) To test the effect of XZ45 on HSV recombination in infected cells, 8LacZ (UL29 mutant)
and hr99 (UL5 mutant) viruses were used to coinfect HEp-2 cells in the presence of increasing concentrations of either XZ45 or PAA. At 20 h after infection,
progeny viruses were harvested and titrated on Vero cells and V529 cells to determine the viral titer of recombinant virus and total virus, respectively. The
recombination frequency was determined by calculating the ratio of the titer of recombinant virus to total virus. The recombination rate for control DMSO-
treated cells was 13.7%. (B) Effect of XZ45 on in vitro D-loop formation. An ICP8-dependent D-loop assay was conducted in the absence or the presence of
various concentrations of XZ45. (C) Effect of XZ45 on ICP8 DNA binding in an electrophoretic mobility shift assay. ICP8 was incubated with a labeled ssDNA
oligomerwithorwithoutXZ45atvariousconcentrationsandthensubjectedtoelectrophoresis.(D)EffectofXZ45onICP8DNAbindingintwoinvitroassays.
(Top) ssDNA-bead pulldown assay using HSV-1-infected-cell lysates and oligo(dT)25-conjugated beads. For lanes 1, DMSO was added during infection,
pulldown,andwashing.Forlanes2,DMSOwasaddedduringinfection,andXZ45(10M)wasaddedduringlysisandincubation.Forlanes3,XZ45wasadded
at infection, to lysates, and during incubation. ICP8 was identiﬁed by immunoblotting. (Bottom) Two exposures of a Western blot showing ICP8 binding to
ssDNA-cellulose.HEp-2cellswereinfectedwithHSV-1atanMOIof10for6hinthepresenceorabsenceof10MXZ45.Theinfectedcellswerethenlysed,the
soluble fraction of the extracts was applied to the column, and the bound proteins were eluted with increasing NaCl concentrations, as indicated. ICP8 was
identiﬁed by immunoblotting. The lower panel reﬂects a longer exposure.
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infection. It is conceivable that the KSHV ORF6 DNA-binding
protein has a role in promoting the viral chromatin structure
changes that are observed during reactivation from latent infec-
tion (32, 33).
Certain of the other herpesviruses, such as human herpesvirus
6 (HHV-6) and Marek’s disease herpesvirus, integrate into the
host cell chromosome and persist in this novel form of latent
infection (34–37). It is conceivable that the viral ICP8 homologs
have a role in the integration or excision process through their
recombinase activities and might be a target for this class of anti-
viral compounds.
Development of resistance. Further studies will be needed to
determine if it is possible for the herpesviruses to mutate to resis-
tancetothesecompoundsand,ifso,toidentifythepossiblemech-
anismsofresistancetotheseinhibitors.Weattemptedtoselectfor
an HSV-1 variant that was resistant to XZ45, but passage of virus
in increasing concentrations of XZ45 led to a virus that showed
slightlyincreasedreplicationrelativetoWTvirusintheabsenceor
the presence of XZ45 (S. M. Gregory, R. C. Colgrove, and D. M.
Knipe, unpublished results). Illumina sequencing of the genome
oftheselectedvirusshowedonlythreemutationsinopenreading
frames, all in the ICP4 gene, which could explain the increased
viral replication in general. Therefore, it may be difﬁcult to select
for resistance to this type of compound for any of several reasons,
including(i)decreasedviralﬁtnessoftheresistantvirus,(ii)mul-
tiple viral targets, or (iii) a host target that is more important for
viral replication than cell growth.
Structure-activity relationships of the compounds tested.
We found that the hydrazide and oxoisoindole compounds were
the most potent for inhibition of HSV-1 replication. The XZ45
hydrazide compound was chosen for further study because it
showed good antiviral activity and limited cytotoxicity. Identiﬁ-
cation of the target molecule(s) will be needed to determine why
the hydrazide compounds provide selectivity for viral replication.
The different herpesviruses may also have different patterns of
sensitivity, so each will need to be screened with this and other
panels of compounds. The libraries of compounds from HIV in-
tegrase inhibitor screens could be sources of additional com-
pounds that have anti-herpes activity.
This study forms the foundation for the development and
study of a new class of herpesvirus family antivirals that could
complement the nucleoside analogs, which target the viral DNA
polymerase, or new antivirals that target the helicase-primase
complex. Much needs to be done to follow up on these initial
observations, including identiﬁcation of the target(s), detailed
analysis of structure-activity relationships, and deﬁnition of the
mechanism of inhibition. There is a particular need for new anti-
viral drugs for HCMV, HHV-6, and KSHV, which this approach
might provide. HCMV seemed to be especially sensitive to our
lead compound, so this could be a very proﬁtable lead to develop
further as a therapeutic for clinical application. The potential of
developing drugs that inhibit both HIV and herpesvirus infection
makesthisclassofcompoundsaveryattractiveapproachfordrug
development.HSVprovidesafacilesystemforstudyingherpesvi-
rallyticinfectionandthebiochemicalandmolecularmechanisms
FIG 6 Effect of XZ45 on HCMV replication. HCMV yield reduction assay
withXZ45,performedinHFFcellsasdescribedforFig.1,exceptthatprogeny
virus was harvested at 5 dpi.
FIG 7 Effect of XZ45 on KSHV gene expression during reactivation. HEK293 cells latently infected with rKSHV.219 (293rKSHV.219) were reactivated with
20 ng/ml of PMA and 30 mM VA and treated with 10 M of XZ45 or DMSO for 48 h. Total RNA was isolated, and the levels of ORF57 (A) and ORF64 (B)
transcriptsweremeasuredbyqRT-PCR.Viraltranscriptlevelswerenormalizedtocellular18SrRNAlevels.Barsrepresentmeansstandarderrorsofthemeans
(n  3). One-way analysis of variance with repeated measures was followed by the Bonferroni posttest. **, P  0.01.
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theotherherpesvirusesprovidesystemsforstudyingtheestablish-
ment of and reactivation from latent infection and some infec-
tious agents with great medical need for new strategies for inter-
vention.
MATERIALS AND METHODS
Cellsandviruses.HEp-2cells,Verocells,andhumanfetalforeskinﬁbro-
blasts(HFFs)wereobtainedfromtheAmericanTypeCultureCollection.
V5-29 cells are Vero cells that been transformed with the HSV UL5 and
UL29 genes (38). The 293rKSHV.219 cells (39) were provided by Jae Jung
(University of Southern California). Cells were propagated as described
previously (11).
HSV-1 WT KOS virus (40) was grown and titrated on Vero cells. The
low-passage-numberHSV-1strainF(41)andHSV-2strainG(41)viruses
were provided by Bernard Roizman (University of Chicago). The HSV-1
8lacZ virus (42) containing a lacZ fusion to ICP8 and the HSV-1 hr99
virus (43) provided by Sandy Weller (University of Connecticut) and
containing a lacZ insertion in the UL5 gene were grown and titrated on
V5-29 cells. Human cytomegalovirus strain AD169 was grown and
titrated on HFF cells.
HSV growth assays were as described previously (11). Human CMV
growth assays were as described previously (44). KSHV reactivation from
latentinfectionin293rKSHVcellswasconductedasdescribedpreviously
(23).AnalysisofviralproteinexpressionbyWesternblottingandanalysis
of viral DNA replication by real-time PCR were conducted as described
previously (11).
HIV integrase inhibitors. Raltegravir and 118-D-24 were originally
obtained from the NIAID AIDS Reagents Repository. Additional com-
pounds from the Zhao and Burke laboratories included diketo acids
XZ319andXZ320,oxoisoindolesXZ89,XZ90,XZ99,XZ100,andXZ259,
hydrazidesXZ45,XZ15,XZ49,XZ48,andXZ50,andpyridinonesXZ199,
XZ202, XZ201, XZ220, XZ256, XZ242, XZ248, XZ235, and XZ236 (see
Table S1 in the supplemental material for structures and references for
these HIV-1 integrase inhibitors).
Puriﬁcation of ICP8 and biochemical studies. ICP8 was puriﬁed as
described previously from baculovirus vector-infected SF21 insect cells
(11). EMSA was performed as described previously (11). A 25-mer oli-
go(dT) oligonucleotide [oligo(dT)25] (Integrated DNA Technologies)
was phosphorylated at its 5= end with T4 polynucleotide kinase (NEB)
using [-32P]ATP (6,000 Ci/mmol, 10 mCi/ml; PerkinElmer), and unin-
corporatedradioactivenucleotideswereremovedusinganillustraMicro-
SpinG-50column(GEHealthcare).Approximately2pmolofoligo(dT)25
(basedontheassumptionof100%recoveryfromtheMicroSpincolumn)
was incubated on ice with the indicated concentration of ICP8 with or
withoutdruginICP8storagebufferfor30min.Thesampleswereresolved
in a 5% native polyacrylamide gel, and the gel was dried and exposed to a
phosphor storage screen for imaging. In vitro ICP8 DNA-binding assays
were conducted as described previously (11, 45).
The DNA strand exchange assay reaction was performed as described
previously (13) using ICP8 puriﬁed as described above, pUC18 plasmid,
and 32P-labeled pUC-18 PB11 oligomer. After incubation, the reaction
mixturewasdigestedwithproteinaseK,andtheproductswereresolvedin
a 1.2% agarose gel. The gel was dried and subjected to autoradiography.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01318-14/-/DCSupplemental.
Table S1, DOC ﬁle, 0.7 MB.
Figure S1, TIF ﬁle, 8 MB.
ACKNOWLEDGMENTS
This research was supported by NIH grant AI063106 and a Feasibility
Project Award from the Harvard University Center for AIDS research
grant (P30 AI060354) to D.M.K.
We acknowledge the NIAID Division of AIDS Reagent Repository for
raltegravirand118-D-24.WethankBlairStrangforadviceontheHCMV
yield reduction assays.
REFERENCES
1. Roizman B, Knipe DM, Whitley RJ. 2013. Herpes simplex viruses, p
1823–1897. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lip-
pincott Williams & Wilkins, Philadelphia, PA.
2. Coen DM, Richman DD. 2013. Antiviral agents, p 338–374. In Knipe
DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams &
Wilkins, Philadelphia, PA.
3. van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD,
Remeijer L, Verjans GM. 2013. Acyclovir prophylaxis predisposes to
antiviral-resistant recurrent herpetic keratitis. J. Infect. Dis. 208:
1359–1365. http://dx.doi.org/10.1093/infdis/jit350.
4. Pan D, Kaye SB, Hopkins M, Kirwan R, Hart IJ, Coen DM. 2014.
Common and new acyclovir resistant herpes simplex virus-1 mutants
causing bilateral recurrent herpetic keratitis in an immunocompetent pa-
tient. J. Infect. Dis. 209:345–349. http://dx.doi.org/10.1093/infdis/jit437.
5. Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston
C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack
HP, Ruebsamen-Schaeff H, Birkmann A. 2014. Helicase-primase inhib-
itor pritelivir for HSV-2 infection. N. Engl. J. Med. 370:201–210. http://
dx.doi.org/10.1056/NEJMoa1301150.
6. FreedE,MartinM.2013.Humanimmunodeﬁciencyviruses:replication,
p 1502–1561. In Knipe DM, Howley PM (ed), Fields virology, 6th ed.
Lippincott Williams & Wilkins, Philadelphia, PA.
7. Di Santo R. 2014. Inhibiting the HIV integration process: past, present,
and the future. J. Med. Chem. 57:539–566. http://dx.doi.org/10.1021/
jm400674a.
8. Cherepanov P, Maertens GN, Hare S. 2011. Structural insights into the
retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21:
249–256. http://dx.doi.org/10.1016/j.sbi.2010.12.005.
9. Selvarajan Sigamani S, Zhao H, Kamau YN, Baines JD, Tang L. 2013.
The structure of the herpes simplex virus DNA-packaging terminase
pUL15 nuclease domain suggests an evolutionary lineage among eukary-
otic and prokaryotic viruses. J. Virol. 87:7140–7148. http://dx.doi.org/
10.1128/JVI.00311-13.
10. Nadal M, Mas PJ, Blanco AG, Arnan C, Solà M, Hart DJ, Coll M. 2010.
Structure and inhibition of herpesvirus DNA packaging terminase nu-
clease domain. Proc. Natl. Acad. Sci. U. S. A. 107:16078–16083. http://
dx.doi.org/10.1073/pnas.1007144107.
11. Bryant KF, Yan Z, Dreyfus DH, Knipe DM. 2012. Identiﬁcation of a
divalentmetalcationbindingsiteinherpessimplexvirus1(HSV-1)ICP8
required for HSV replication. J. Virol. 86:6825–6834. http://dx.doi.org/
10.1128/JVI.00374-12.
12. Dreyfus DH. 2009. Paleo-immunology: evidence consistent with inser-
tion of a primordial herpes virus-like element in the origins of acquired
immunity. PLoS One 4:e5778. http://dx.doi.org/10.1371/
journal.pone.0005778.
13. Nimonkar AV, Boehmer PE. 2003. The herpes simplex virus type-1
single-strand DNA-binding protein (ICP8) promotes strand invasion. J.
Biol. Chem. 278:9678–9682. http://dx.doi.org/10.1074/jbc.M212555200.
14. Reuven NB, Staire AE, Myers RS, Weller SK. 2003. The herpes simplex
virus type 1 alkaline nuclease and single-stranded DNA binding protein
mediate strand exchange in vitro. J. Virol. 77:7425–7433. http://
dx.doi.org/10.1128/JVI.77.13.7425-7433.2003.
15. Conley AJ, Knipe DM, Jones PC, Roizman B. 1981. Molecular genetics
of herpes simplex virus. VII. Characterization of a temperature-sensitive
mutant produced by in vitro mutagenesis and defective in DNA synthesis
and accumulation of gamma polypeptides. J. Virol. 37:191–206.
16. Baines JD, Poon AP, Rovnak J, Roizman B. 1994. The herpes simplex
virus 1 U(L)15 gene encodes two proteins and is required for cleavage of
genomic viral DNA. J. Virol. 68:8118–8124.
17. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel
RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning
L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics,
andtolerabilityofMK-0518,anovelinhibitorofHIV-1integrase,dosedas
monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
J. Acquir. Immune Deﬁc. Syndr. 43:509–515. http://dx.doi.org/10.1097/
QAI.0b013e31802b4956.
18. Zhangm X, Pais GC, Svarovskaia ES, Marchand C, Johnson AA, Karki
HIV Integrase Inhibitors Block Herpesviruses
July/August 2014 Volume 5 Issue 4 e01318-14
® mbio.asm.org 7RG, Nicklaus MC, Pathak VK, Pommier Y, Burke TR. 2003. Azido-
containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg. Med.
Chem. Lett. 24:1215–1219.
19. Zhao XZ, Semenova EA, Vu BC, Maddali K, Marchand C, Hughes SH,
Pommier Y, Burke TR. 2008. 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-
1-one-based HIV-1 integrase inhibitors. J. Med. Chem. 51:251–259.
http://dx.doi.org/10.1021/jm070715d.
20. Pellett P, Roizman B. 2013. Herpesviridae, p 1802–1823. In Knipe DM,
Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins,
Philadelphia, PA.
21. Ozgur S, Damania B, Grifﬁth J. 2011. The Kaposi’s sarcoma-associated
herpesvirusORF6DNAbindingproteinformslongDNA-freehelicalpro-
tein ﬁlaments. J. Struct. Biol. 174:37–43. http://dx.doi.org/10.1016/
j.jsb.2010.10.015.
22. Deng B, O’Connor CM, Kedes DH, Zhou ZH. 2007. Direct visualization
oftheputativeportalintheKaposi’ssarcoma-associatedherpesviruscap-
sid by cryoelectron tomography. J. Virol. 81:3640–3644. http://
dx.doi.org/10.1128/JVI.02254-06.
23. Shin HJ, DeCotiis J, Giron M, Palmeri D, Lukac DM. 2014. Histone
deacetylaseclassesIandIIregulateKaposi’ssarcoma-associatedherpesvi-
rus reactivation. J. Virol. 88:1281–1292. http://dx.doi.org/10.1128/
JVI.02665-13.
24. Andrei G, Snoeck R. 2013. Herpes simplex virus drug-resistance: new
mutations and insights. Curr. Opin. Infect. Dis. 26:551–560. http://
dx.doi.org/10.1097/QCO.0000000000000015.
25. Dreyfus DH. 2013. Evidence that raltegravir (Isentress, Merck), a retro-
viral integrase inhibitor is effective against recurrent human herpes sim-
plex virus infection associated with NK-cell deﬁciency. Pediatr. Ther.
3:172. http://dx.doi.org/10.4172/2161-0665.1000172.
26. ChallbergMD.1986.Amethodforidentifyingtheviralgenesrequiredfor
herpesvirusDNAreplication.Proc.Natl.Acad.Sci.U.S.A.83:9094–9098.
http://dx.doi.org/10.1073/pnas.83.23.9094.
27. Roizman B, Jacob RJ, Knipe DM, Morse LS, Ruyechan WT. 1979. On
the structure, functional equivalence, and replication of the four arrange-
ments of herpes simplex virus DNA. Cold Spring Harb. Symp. Quant.
Biol. 43:809–826.
28. Nimonkar AV, Boehmer PE. 2003. Reconstitution of recombination-
dependentDNAsynthesisinherpessimplexvirus1.Proc.Natl.Acad.Sci.
U. S. A. 100:10201–10206. http://dx.doi.org/10.1073/pnas.1534569100.
29. Wilkinson DE, Weller SK. 2003. The role of DNA recombination in
herpes simplex virus DNA replication. IUBMB Life 55:451–458. http://
dx.doi.org/10.1080/15216540310001612237.
30. Gao M, Knipe DM. 1991. Potential role for herpes simplex virus ICP8
DNA replication protein in stimulation of late gene expression. J. Virol.
65:2666–2675.
31. Mavromara-Nazos P, Roizman B. 1987. Activation of herpes simplex
virus 1 gamma 2 genes by viral DNA replication. Virology 161:593–598.
http://dx.doi.org/10.1016/0042-6822(87)90156-5.
32. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S,
Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis
of KSHV latent and lytic genomes. PLoS Pathog. 6:e1001013. http://
dx.doi.org/10.1371/journal.ppat.1001013.
33. Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M,
Margolis D, Nieto A, Nevels M, Parks JR, Kristie TM. 2013. Snapshots:
Chromatin control of viral infection. Virology 435:141–156. http://
dx.doi.org/10.1016/j.virol.2012.09.023.
34. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, Carnahan
JA, Yoo C, Lofthus GK, McDermott MP. 2008. Chromosomal integra-
tion of human herpesvirus 6 is the major mode of congenital human
herpesvirus 6 infection. Pediatrics 122:513–520. http://dx.doi.org/
10.1542/peds.2007-2838.
35. Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N. 1992.
Epstein-Barr virus integration in human lymphomas and lymphoid cell
lines. Cancer 70:185–191. http://dx.doi.org/10.1002/1097
-0142(19920701)70:1185::AID-CNCR28207001293.0.CO;2-J.
36. Delecluse HJ, Schüller S, Hammerschmidt W. 1993. Latent Marek’s
disease virus can be activated from its chromosomally integrated state in
herpesvirus-transformed lymphoma cells. EMBO J. 12:3277–3286.
37. Luppi M, Marasca R, Barozzi P, Ferrari S, Ceccherini-Nelli L, Batoni G,
Merelli E, Torelli G. 1993. Three cases of human herpesvirus-6 latent
infection: integration of viral genome in peripheral blood mononuclear
cell DNA. J. Med. Virol. 40:44–52. http://dx.doi.org/10.1002/
jmv.1890400110.
38. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. 2000.
Construction, phenotypic analysis, and immunogenicity of a UL5/UL29
double deletion mutant of herpes simplex virus 2. J. Virol. 74:7963–7971.
http://dx.doi.org/10.1128/JVI.74.17.7963-7971.2000.
39. Inn KS, Lee SH, Rathbun JY, Wong LY, Toth Z, Machida K, Ou JH,
Jung JU. 2011. Inhibition of RIG-I-mediated signaling by Kaposi’s
sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J. Virol.
85:10899–10904. http://dx.doi.org/10.1128/JVI.00690-11.
40. Schaffer P, Vonka V, Lewis R, Benyesh-Melnick M. 1970. Temperature-
sensitive mutants of herpes simplex virus. Virology 42:1144–1146. http://
dx.doi.org/10.1016/0042-6822(70)90364-8.
41. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes
simplexvirusstrainsdifferingintheireffectonsocialbehaviorofinfected
cells. J. Gen. Virol. 2:357–364. http://dx.doi.org/10.1099/0022-1317-2-3
-357.
42. GaoM,KnipeDM.1989.Geneticevidenceformultiplenuclearfunctions
of the herpes simplex virus ICP8 DNA-binding protein. J. Virol. 63:
5258–5267.
43. Zhu LA, Weller SK. 1992. The UL5 gene of herpes simplex virus type 1:
isolationofalacZinsertionmutantandassociationoftheUL5geneprod-
uct with other members of the helicase-primase complex. J. Virol. 66:
458–468.
44. Strang BL, Boulant S, Chang L, Knipe DM, Kirchhausen T, Coen DM.
2012.HumancytomegalovirusUL44concentratesattheperipheryofrep-
lication compartments, the site of viral DNA synthesis. J. Virol. 86:
2089–2095. http://dx.doi.org/10.1128/JVI.06720-11.
45. Knipe DM, Quinlan MP, Spang AE. 1982. Characterization of two
conformational forms of the major DNA-binding protein encoded by
herpes simplex virus 1. J. Virol. 44:736–741.
Yan et al.
8
® mbio.asm.org July/August 2014 Volume 5 Issue 4 e01318-14